Business
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
MENLO PARK, Calif., February 26, 2026--Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). STK-012, a first-in-class α/β-IL-2 receptor biased partial agonist, will be evaluated in combination with standard of care chemotherapy and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed cell death receptor-1) therapy, in the ong
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2412,"height":503,"url":"https://media.zenfs.com/en/business-wire.com/cc52becf79c9b28bb2e4836135d949a4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZuodX9jDCyJdP0.lobJ4ZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cc52becf79c9b28bb2e4836135d949a4","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sqDsAcQ5oZOH4MVwfxtqPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cc52becf79c9b28bb2e4836135d949a4","width":1200,"height":250}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., February 26, 2026--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). STK-012, a first-in-class α/β-IL-2 receptor biased partial agonist, will be evaluated in combination with standard of care chemotherapy and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed cell death receptor-1) therapy, in the ongoing SYNERGY-101 randomized Phase 2 study in first-line, PD-L1 negative nonsquamous (NSQ) non-small cell lung cancer (NSCLC).","length":642,"tagName":"p"},{"type":"text","content":""In our Phase 1b study, STK-012 in combination with pembrolizumab and chemotherapy has shown promising efficacy in first-line PD-L1 negative NSQ NSCLC patients, with a 50% response rate in this population presented at the Society for Immunotherapy of Cancer Annual Meeting 2025," said Debanjan Ray, Chief Executive Officer of Synthekine. "We are excited to collaborate with Merck on our randomized Phase 2 study to further demonstrate the potential of this combination to deliver improved clinical outcomes for these patients, who receive limited benefit from current standard of care therapies."","length":616,"tagName":"p"},{"type":"text","content":"STK-012 is a first-in-class α/β-IL-2 receptor biased partial agonist engineered to selectively stimulate antigen-activated T cells, which are associated with potent anti-tumor activity, and avoid broad stimulation of other lymphocytes, such as natural kill...